

AI Sight – Summary

Overview

- University of Liverpool (UoL) spin-out revolutionizing diabetic eye screening with AI-powered retinal image analysis.
- Replaces up to 80% of human graders, reducing cost and turnaround time.
- Uses comparative judgment AI — a world-first in medical imaging — delivering exceptional accuracy in detecting sight-threatening disease.
- Operates as a batch reporting platform or intuitive GUI system.

Progress Since Last Round

1. Research & Validation

- Partnership with InHealth Intelligence, the UK's largest retinal screening provider.
- 80,000-image validation confirmed accuracy exceeding competitors and national standards.
- 100% detection accuracy for R3 (sight-threatening) disease.
- Load-tested and usability-approved, leading to GUI refinements and strong end-user feedback.

2. Team & Leadership

- **Peter George (Chair)** – 40+ years in healthcare; ex-CEO, *Clinigen plc*; advisor to Oxford spin-outs.
- **Steve Powell – CEO & Co-Founder** - Experienced healthcare entrepreneur with a background in scaling medical ventures from concept to commercialisation.
- **Professor Simon Harding – Co-Founder & Chief Medical Officer** - Internationally recognised ophthalmologist and academic at the University of Liverpool, specialising in diabetic eye disease and clinical translation of AI diagnostics.
- **David Lovett (Board Observer)** – ex-MD, *Perceptive Engineering* (acquired by Applied Materials).
- **Phil Kirby (Board Observer)** – Founder, *InHealth Intelligence*; 13 years in NHS IT.
- Supported by UoL's research collaboration and facilities, maintaining academic and clinical credibility.

3. Regulatory Achievements

- UKCA marking (Class I) achieved.
- CE marking (Class IIa) in final stages – BSI Stage I audit passed first time.
- ISO 13485 certification with zero non-conformities.

4. Product Development

- Evolved from prototype to fully market-ready system with integrated billing, user tracking, and analytics.
- Evaluated by clinicians and industry experts.

5. Commercial Traction

- InHealth integrating AI Sight into its Spectra platform; business case for adoption underway.
- Canon in discussions for hardware integration — significant global potential.

Next 6-Month Milestones

1. Finalize Class IIa/CE certification.
2. Secure InHealth contracts.
3. Controlled product launch and field testing.
4. Establish international partnerships for expansion.

Funding & Financials

- Raise: £1.5M total; DBC LS investing £250K (alongside *LCR Seed & River Capital*).
- UoL remains an institutional shareholder.
- First sales: Expected 2026.
- Post-CE valuation: £6–8M.
- Projected exit (2028): £100M+ potential via trade sale/acquisition.
- Investor return: >10x if revenue reaches £24M (4–6x revenue multiple).

Investment Opportunity

- Clinically proven, regulatory-ready AI technology addressing a major global healthcare need.
- Experienced leadership, academic credibility (UoL), and strong commercial partnerships.
- Positioned for rapid growth, market entry, and high-value exit within 3–5 years.